CombiGene

📍 Lidingö, Sweden🗓 Founded 2008👥 14 employees💰 Last funded May 2021
Biotechnology Research🌐 combigene.com
Website LinkedIn
CombiGene’s business concept is to develop effective gene therapies for treatment of difficult-to-treat diseases for which adequate treatment methods are currently lacking. The company intends to take its candidate drugs through the phases of preclinical development and initial clinical studies under its own management, and subsequently continue development and commercialization under its own management or in collaboration with other partners. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace Nasdaq First North and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se . For further information, please visit www.combigene.com. CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
2008
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Sweden
1
Denmark
1
Frequently asked questions
Who invested in CombiGene?
CombiGene has 2 investors on record on gritt.io.
When did CombiGene last raise funding?
The most recent investment in CombiGene recorded on gritt.io was in May 2021.
When was CombiGene founded?
CombiGene was founded in 2008.
What industry is CombiGene in?
CombiGene operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is CombiGene based?
CombiGene is headquartered in Lidingö, Sweden.